Devonian preclinical data support Thykamine

Executive Summary

• Devonian Health Group disclosed additional gene‑expression data from its STAM mouse model of metabolic dysfunction‑associated steatohepatitis (MASH), further confirming the anti‑inflammatory and anti‑fibrotic activity of Thykamine.
• At the highest dose (50 mg/kg), Thykamine markedly down‑regulated 29 fibrosis‑ and inflammation‑related genes, with many showing 80–90 % reductions versus placebo.
• The results demonstrate a dose‑dependent, region‑specific molecular effect in the liver and will be included in an upcoming scientific publication.

Key Details

• Study Design: Oral Thykamine administered once daily for three weeks at 0.5 mg/kg, 5 mg/kg, and 50 mg/kg in the STAM mouse model of MASH.
• Gene Panel: Expression of 29 genes evaluated (13 fibrosis‑related, 5 inflammation‑related, 11 involved in both pathways).
• Key Fibrosis Genes Down‑regulated: CCN1, CCN2, COL1A1, COL1A2, COL5A2, JAG1, MMP2, MMP13, SERPINE1, SERPINE2, SNAI1, TGFBR1.
• Key Inflammation Genes Down‑regulated: CCL2, CCR2, IFNG, MMO8.
• Dual‑Pathway Genes Down‑regulated: COL3A1, COL6A1, FN1, TGFB1, TIMP1, MMP14, TNF, IL10, TLR4.
• Magnitude of Effect: Several genes exhibited 80–90 % reduction relative to placebo at the 50 mg/kg dose.
• Dose‑Response: Consistent, pharmacologically driven reductions observed across low, mid, and high doses.
• Regional Variation: Gene expression differed between caudal and lateral liver lobes, indicating localized activity of Thykamine.
• Analytical Methods: PCR performed by Dr. Louis Flamand (Université Laval); statistical analysis by Dr. John Sampalis (McGill University).
• Future Publication: Complete gene‑expression dataset to be included in a planned peer‑reviewed article on the STAM MASH preclinical study.

Notable Quotes

“We are delighted to share these gene expression results, which provide important molecular confirmation of the anti‑inflammatory and anti‑fibrotic effects of Thykamine observed in the STAM MASH model,” – Dr. Andre P. Boulet, CEO, Devonian Health Group.

“By demonstrating consistent effects at both the histological and molecular levels, these results strengthen Thykamine’s positioning across a broad array of inflammatory diseases…” – Dr. Andre P. Boulet, CEO, Devonian Health Group.